We sit down with Dr. Joseph Tucker, CEO of MagicMed Industries. During his two decades of biotechnology C-Suite leadership Dr. Tucker cofounded four companies, taking two public and selling one, while the fourth remains an operating private company. He has raised tens of millions of dollars from investors in the United States, Europe and Canada, during which time his teams took seven drugs into FDA, EMA, and HC-approved clinical trials. Among other achievements Dr. Tucker, in collaboration with Dr. Peter Facchini, was the first to sequence the entire genome of the commercially relevant Papaver somniferum, is a co-inventor of cardiovascular drug candidate APABETALONE, and is the discoverer of the human blindness-associated gene SLC24A1. Dr. Tucker has published in high-ranking journals such as Nature Biotechnology and Nature Chemical Biology, has been interviewed by national newspapers and television, is an inventor on 7 issued and 15 pending patents, and holds a Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.